Specifically, AML cell lines, including TP53 wild-type (MOLM-13 and MV4-11) and TP53 mutant (SKM1 and THP1) cells, were treated with various concentrations of cytarabine (0, 0.25, 0.5, 1, 2, and 4 μM). The gene discussed is TP53; the disease is acute myeloid leukemia.